The IL11 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with targeted disruption of the human IL11 gene in the KYSE-30 esophageal squamous cell carcinoma line. This loss-of-function model is provided as a heterogeneous pool, allowing investigators to examine IL-11 cytokine signaling without the constraints of single-cell cloning. The IL11 gene encodes interleukin-11, a pleiotropic cytokine implicated in hematopoiesis, epithelial proliferation, and tissue fibrosis.
The KYSE-30 parent cell line originates from a well-differentiated esophageal squamous cell carcinoma and harbors a TP53 mutation. It displays adherent epithelial morphology and is a standard in vitro paradigm for studying invasion, metastasis, and oncogenic signal transduction in esophageal cancer.
Mechanistically, IL-11 binds the IL-11R?? and gp130 co-receptor, activating JAK1/2 kinases and leading to the phosphorylation of STAT3 and ERK1/2. Downstream targets include the STAT3-responsive genes SOCS3, CCND1, and BCL2L1, as well as MMPs that promote invasion. Upstream regulators such as TGF-??1, IL-1??, TNF-??, NF-??B, STAT3, and AP-1 drive IL11 expression, forming a positive feedback loop. The JAK/STAT3 and MAPK/ERK pathways, along with PI3K/AKT and TGF-?? signaling, mediate the diverse biological outputs of IL-11.
In esophageal cancer, autocrine IL-11 signaling sustains malignant phenotypes, and the KYSE-30 line is believed to depend on this circuitry. Knockout of IL11 disrupts the feedforward loop, reducing STAT3 and ERK1/2 activation and consequently dampening proliferation, survival, and invasive capacity. This polyclonal model thus serves as a powerful system to dissect IL-11-dependent oncogenesis and to explore therapeutic vulnerabilities in esophageal squamous cell carcinoma.
The knockout cells are applicable in western blotting for phospho-STAT3 and phospho-ERK, RT-qPCR for SOCS3 and CCND1, MTT or colony formation assays, Transwell migration and invasion studies, and ELISA for secreted IL-11. They can be employed in xenograft models and immunohistochemistry for Ki-67 and phospho-STAT3. Furthermore, the cells facilitate drug screening for JAK/STAT inhibitors, investigation of tumor-stroma crosstalk, and transcriptomic analyses. Contact Ascent Research for additional information.
